fda warning letters compounding semaglutide september 2025 Beyond the Headlines: to GLP-1 Compounders GLP-1 Compounding: When Innovation May

Strong signals are not the same thing as definitive comparative evidence

All products offered by Aegis Peptides are strictly for laboratory and scientific research purposes only

For continuation versus noncontinuation, the weighted prevalence ratios were 1.29 (95 percent confidence interval, 0.82 to 2.06), 1.08 (95 percent confidence interval, 0.84 to 1.40), and 1.21 (95 percent confidence interval, 0.83 to 1.82) for small for gestational age, large for gestational age, and MCM, respectively."Accumulated evidence provides some reassurance about risk for malformations after inadvertent exposure in women who become pregnant while using GLP-1 RAs," the authors write.Abstract/Full Text (subscription or payment may be required).Sign up for our weekly HealthDay newsletter

Alcohol does not directly interfere with semaglutide's mechanism of action or pharmacokinetics

This isn't about one being 'better' than the other

SGLT2 inhibitors and GLP-1 receptor agonists in diabetic kidney disease: evolving evidence and clinical application